#United States #Los Angeles #Schall Law Firm #Securities Fraud #MoonLake Immunotherapeutics

Legal Action Against MoonLake Immunotherapeutics

The Schall Law Firm, based in Los Angeles, is currently inviting investors to participate in a class action lawsuit concerning alleged securities fraud committed by MoonLake Immunotherapeutics (NASDAQ: MLTX). This lawsuit targets violations connected to the Securities Exchange Act of 1934, particularly focusing on false claims made by MoonLake regarding its drug candidate, sonelokimab (SLK).

Background of the Case

The legal dispute centers on accusations that MoonLake misled investors by presenting sonelokimab as a superior alternative to other monoclonal antibodies. Throughout the class period—spanning from March 10, 2024, to September 29, 2025—the company consistently asserted advantages of SLK that it knew were unfounded. Analysts have referred to the results from a Phase 3 clinical trial of SLK as “disastrous,” resulting in a substantial loss of investor confidence and a nearly 90% decline in the company’s stock value.

Investor Rights

Investors who acquired MoonLake’s securities during the specified time frame are encouraged to reach out to the Schall Law Firm before December 15, 2025, to discuss their rights and potentially participate in the lawsuit. Details regarding participation can be accessed on the law firm's website or by contacting them directly at their Los Angeles office.

Contact Information

For more information, investors can contact Brian Schall of the Schall Law Firm at:

• - Phone: 310-301-3335
• - Address: 2049 Century Park East, Suite 2460, Los Angeles, CA 90067
• - Website: www.schallfirm.com

This lawsuit aims to hold MoonLake accountable for its alleged deceptive practices, which have resulted in financial losses for its investors. As of now, the class has not yet been certified, meaning that without action, investors will remain unrepresented in this matter.

Claim of Misleading Information

The crux of the complaint lies in the assertion that MoonLake deliberately issued false and misleading statements concerning the efficacy and safety of sonelokimab. The company's announcements failed to present the truthful data, hiding the fact that SLK had no exceptional benefits compared to existing treatments. Once the truth became clear, it severely impacted the company's stock price, leading to notable losses endured by shareholders.

Conclusion

Investors now have the opportunity to recuperate their losses by joining the class action against MoonLake Immunotherapeutics. This scenario demonstrates the importance of transparency and accountability within corporate governance, especially for publicly traded entities. For those impacted, acting swiftly to engage with legal representation could be crucial in preserving their rights and potential recovery from this situation.